title: Daratumumab and its potential in the treatment of multiple myeloma: overview of the preclinical and clinical development.
abstract: Despite the recent major advancement in therapy for multiple myeloma, it remains an incurable disease. There remains an unmet need for novel therapies that target different mechanisms of action. Immunotherapy with monoclonal antibodies is a promising area of development and will expand our therapeutic armamentarium in the fight against myeloma. Daratumumab is a novel, high-affinity, therapeutic human monoclonal antibody against unique CD38 epitope with broad-spectrum killing activity. It has a favorable safety profile as monotherapy in patients with relapsed/refractory myeloma and also demonstrates significant single-agent activity. Abundant preclinical data supports its use in combination therapy and clinical studies on various exciting combinations are underway. This review focuses on the CD38 antigen and its targeting with daratumumab and provides an update on the results of recent clinical studies involving daratumumab.
authors.affiliation: Department of Hematology, Singapore General Hospital, Singapore.
authors.forename: Colin
authors.initials: C
authors.lastname: Phipps
authors.affiliation: Department of Hematology, Singapore General Hospital, Singapore.
authors.forename: Yunxin
authors.initials: Y
authors.lastname: Chen
authors.affiliation: Department of Hematology, Singapore General Hospital, Singapore.
authors.forename: Sathish
authors.initials: S
authors.lastname: Gopalakrishnan
authors.affiliation: Department of Haematology, Singapore General Hospital, Outram Road, Singapore 169608, Republic of Singapore and Raffles Cancer Center, Raffles Hospital, 585 North Bridge Road, #13-00 Raffles Hospital, Singapore, 188770, Singapore.
authors.forename: Daryl
authors.initials: D
authors.lastname: Tan
keywords: daratumumab; monoclonal; myeloma